Discoid Lupus Erythematosus
Research Study
What is it? Discoid lupus erythematosus is a chronic scarring skin condition characterized by persistent scaly plaques on the scalp, face, and ears which can progress to scarring, atrophy, dyspigmentation and permanent hair loss in affected hair-bearing areas.
Current available trials:
- Age 18 to 75 years.
- Diagnosis of discoid lupus erythematosus for at least 6 months or more prior to enrollment.
- Injection once a month, 1 year long, free medications and evaluations, with compensation included.
- Requirements: intermittent blood collection, ECG, physical examination, and images of lesions.
About the HZNP-DAX-202 DLE Study
The HZNP-DAX-202 DLE Study aims to evaluate a new drug for discoid lupus erythematosus (DLE), a skin condition characterized by disc-shaped sores on areas like the face, neck, ears, scalp, hands, and feet. Participants experiencing moderate to severe symptoms despite current medication or intolerance to medication side effects may qualify. This study focuses on individuals whose lupus affects only their skin, not other organs (systemic lupus erythematosus).
Study Details and Participation
The study drug, administered via subcutaneous injection every 4 weeks, targets inflammation differently from existing treatments. During the initial phase, participants have a 66% chance of receiving the study drug or a placebo, followed by all participants receiving the active drug in the subsequent phase. The study spans up to 60 weeks with up to 16 site visits. Participants may continue their current discoid lupus medication and use approved rescue medications during the study.
Participant Benefits and Safety
Participants receive all study-related care and the drug at no charge, with regular monitoring by specialized physicians. This study offers the opportunity to contribute to scientific knowledge about discoid lupus while prioritizing participant safety and privacy throughout the research process.